Novel Fibroblast Growth Factor 1-Derived Peptides for Therapy and Drug Discovery
- 技术优势
- Can bind to FGF receptors and block integrin-FGF receptor cross talk Inhibit FGF signaling in a dominant negative fashion
- 技术应用
- Inhibition of angiogenesis Inhibition of tumor growth Inhibition of inflammation Inhibition of excessive wound healing Reduction of resistance of tumor cells to chemotherapeutic agents Development of assays to discover new compounds that affect FGF signalling
- 详细技术说明
- Fibroblast growth factors (FGFs) regulate diverse cellular processes including growth and differentiation. In addition, aberrant FGF signaling has been implicated in tumor progression. FGFs are also pro-inflammatory growth factors that have been implicated in promoting pathological angiogenesis in chronic inflammatory disease. Therefore, the FGF signaling pathway is an attractive target for cancer and inflammatory disease therapy. However, specific antagonists of this pathway are not well characterised. Researchers at the University of California, Davis have developed novel peptides derived from FGF1 that can bind to FGF receptors and block integrin-FGF receptor cross talk, inhibiting FGF signaling in a dominant negative fashion. These peptides show promise as therapeutic agents and tools for compound discovery for the advancement of cancer therapy and treatment of inflammation.
- *Abstract
-
This technology relates to novel peptides derived from fibroblast growth factor 1 (FGF1). These peptides inhibit cross talk between integrins and FGF receptors in a dominant negative fashion. Since FGF signaling has been implicated in tumor progression and inflammation, this technology shows potential for therapies and drug discovery in cancer biology and inflammatory diseases.
- *IP Issue Date
- May 1, 2012
- *Principal Investigation
-
Name: Seiji Mori
Department:
Name: Yoshikazu Takada
Department:
- 申请号码
- 8168591
- 其他
-
Related Materials
Mori, S., C.Y. Wu, S. Yamaji, J. Saegusa, B. Shi, Z. Ma, Y. Kuwabara, K.S. Lam, R.R. Isseroff, Y.K. Takada, and Y. Takada, Direct Binding of Integrin {alpha}v{beta}3 to FGF1 Plays a Role in FGF1 Signaling. J Biol Chem, 2008. 283(26): p. 18066-75.
Yamaji, S., J. Saegusa, K. Ieguchi, M. Fujita, Y.K. Takada, and Y. Takada, A novel fibroblast growth factor-1 (FGF1) mutant that acts as an FGF antagonist. PLoS One, 2010. 5(4): p. e10273.
Mori, S., V. Tran, K. Nishikawa, T. Kaneda, Y. Hamada, N. Kawaguchi, M. Fujita, Y.K. Takada, N. Matsuura, M. Zhao, and Y. Takada, A Dominant-Negative FGF1 Mutant (the R50E Mutant) Suppresses Tumorigenesis and Angiogenesis. PLoS One, 2013. 8(2): p. e57927.
Mori, S. and Y. Takada, Crosstalk between Fibroblast Growth Factor (FGF) Receptor and Integrin through Direct Integrin Binding to FGF and Resulting Integrin-FGF-FGFR Ternary Complex Formation. Medical Sciences, 2013. 1(1): p. 20-36.Additional Technologies by these Inventors
- Novel Insight into Inhibiting IGF1 Signaling
- Suppression of sPLA2-Integrin Binding for Treating an Inflammatory Condition or Suppressing Cell Proliferation
Tech ID/UC Case
24919/2006-088-0
Related Cases
2006-088-0
- 国家/地区
- 美国
